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Abstract
Aims/hypothesis The NEFA-responsive G-protein coupled re-
ceptor 120 (GPR120) has been implicated in the regulation of
inflammation, in the control of incretin secretion and as a
predisposing factor influencing the development of type 2
diabetes by regulation of islet cell apoptosis. However, there
is still considerable controversy about the tissue distribution of
GPR120 and, in particular, it remains unclear which islet cell
types express this molecule. In the present study, we have
addressed this issue by constructing a Gpr120-knockout/
β-galactosidase (LacZ) knock-in (KO/KI) mouse to examine
the distribution and functional role of GPR120 in the endo-
crine pancreas.
Methods A KO/KI mouse was generated in which exon 1 of
theGpr120 gene (also known as Ffar4) was replaced in frame
by LacZ, thereby allowing for regulated expression of
β-galactosidase under the control of the endogenous
GPR120 promoter. The distribution of GPR120 was inferred
from expression studies detecting β-galactosidase activity and
protein production. Islet hormone secretion was measured
from isolated mouse islets treated with selective GPR120
agonists.
Results β-galactosidase activity was detected as a surrogate
for GPR120 expression exclusively in a small population of
islet endocrine cells located peripherally within the islet man-
tle. Immunofluorescence analysis revealed co-localisation
with somatostatin suggesting that GPR120 is preferentially
produced in islet delta cells. In confirmation of this, glucose-
induced somatostatin secretion was inhibited by a range of
selective GPR120 agonists. This response was lost in
GPR120-knockout mice.
Conclusions/interpretation The results imply that GPR120 is
selectively present within the delta cells of murine islets and
that it regulates somatostatin secretion.
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GPR120 (FFAR4) is preferentially expressed in pancreatic delta
cells and regulates somatostatin secretion from murine islets
of Langerhans
Introduction
The G-protein coupled receptor 120 (GPR120, also classified
as free fatty acid receptor 4 [FFAR4]; www.iuphar-db.org,
accessed 31 January 2014) was identified by Fredriksson
et al [1] and is encoded within four exons located on
chromosome 10q23.33 in humans [2, 3]. De-orphanisation
of this receptor revealed that the ligands for GPR120
include a variety of medium- and long-chain NEFAs,
such as the n-3 species eicosapentaenoic acid (C20:5) and
docosahexaenoic acid (DHA; C22:6). In addition, GPR120
binds various saturated fatty acids (C14–C18) as well as
certain monounsaturated species with chain lengths of C16
and above [4–12].
The expression of GPR120 was confirmed in the small
intestine [6] where it is thought to mediate the increased
release of hormones such as cholecystokinin and glucagon-
like-peptide 1 in response to the intestinal delivery of fatty
acids [6, 13, 14]. Further studies have suggested that GPR120
is also expressed in a number of other tissues, including
adipocytes, taste buds and certain immune cells. In these
contexts, the functional role of GPR120 remains enigmatic
but it has been proposed to be involved in the regulation of
adipogenesis [8, 10, 15], gustation [4, 16, 17], adipocyte
glucose metabolism [10] and various anti-inflammatory
responses [10, 18].
A further tissue in which GPR120 has been identified
by some investigators is the endocrine pancreas but its
expression within islets remains contentious. Initial stud-
ies suggested that Gpr120 (also known as Ffar4)
mRNA is not detectable in whole pancreas, isolated
islets of Langerhans or in certain pancreatic beta cell
lines [6, 14, 19]. However, more recently, we and others
have detected the expression of Gpr120 mRNA in cer-
tain rat beta cell lines as well as in both primary human
and rodent islets of Langerhans [20, 21]. In addition,
GPR120 has been implicated as a regulator of apoptosis
in human islets [22]. Thus, further studies are warranted to
establish the functional role of the receptor in the islets of
Langerhans.
The aim of the present investigation was to exploit a novel
global knockout/knock-in approach in mice to establish more
firmly whether or not GPR120 is present in the islets of
Langerhans. Accordingly, a Gpr120-knockout/β-galactosi-
dase (LacZ) knock-in (KO/KI) mouse was generated in which
exon 1 of the Gpr120 gene was replaced in frame by LacZ,
thereby allowing for regulated expression of β-galactosidase
under the control of the endogenous GPR120 promoter. These
animals were used to study the distribution of β-galactosidase
within mouse pancreas as a means to establish which endo-
crine cell types predominantly express GPR120. The func-
tional consequences of GPR120 expression within islets were
also studied.
Methods
Creation of KO/KI mice A 0.567 kb fragment from exon 1 of
Gpr120 was replaced by a nuclear LacZ expression cassette
(in frame) alongside a LoxP floxed PGK-neo selection marker
in mice from a pure C57bl/6 genetic background in a colony
maintained by AstraZeneca (M. Bjursell, unpublished obser-
vations). The PGK-neo marker was inserted alongside the
LacZ gene allowing for the selection of transgenic embryos
according to antibiotic resistance. Heterozygote animals were
bred against an R26Cre strain to remove the LoxP floxed neo
cassette as a means to yield the final knockout strain. Animals
were genotyped by PCR with primers amplifying differential-
ly sized products from the wild-type (WT) and null alleles.
These studies were conducted in accordance with the Princi-
ples of Laboratory Care.
Generation of cryosections Pancreas and colon sections were
harvested from WT and KO/KI animals, trimmed and orien-
tated onto a cork disk, to which they were attached with
cryomatrix (Thermo Scientific, Cramlington, UK) before be-
ing frozen in isopentane. Serial transverse sections (8 μm)
were cut at −14 or −19°C for the colon and pancreas, respec-
tively. The sections were air-dried for 30 min before being
frozen and stained.
β-galactosidase reporter gene assay Pancreas or colon sec-
tions were warmed to room temperature and fixed for 10 min.
Sections were washed twice in PBS prior to the addition of
X-gal stain (β-galactosidase reporter gene staining kit GALS,
Sigma-Aldrich, St Louis, MO, USA), incubated at 37°C for
3 h and washed in distilled water (dH2O) for 5 min. They were
incubated in nuclear fast red (Al2SO4) for 5 min, washed in
H2O and dehydrated: 1×5 min 95% industrial methylated
spirit (IMS), 2×5 min 100% IMS and 2×5 min xylene. Slides
were viewed and imaged under a light microscope.
Immunofluorescence staining Pancreas tissue was fixed in
buffered 10% formalin, processed to wax blocks and sec-
tioned onto slides (4 μm). Dual fluorescence staining was
performed to determine the islet cell type in which
β-galactosidase/GPR120 was expressed. Anti-insulin (1:500;
Dako, Cambridge, UK), anti-glucagon (1:200; Abcam, Cam-
bridge, UK) and anti-somatostatin (1:100; Millipore, Watford,
UK) were detected using Alexa Fluor-488 conjugated anti-
goat antibody (Abcam) and anti-β-galactosidase (1:1200;
Abcam) with Alexa Fluor-568 conjugated anti-rabbit anti-
body. Citrate buffer (pH 6) was used for antigen retrieval in
the case of β-galactosidase and somatostatin. Briefly, tissue
sections were fixed, de-waxed and rehydrated prior to antigen
retrieval (heating in a microwave at full power for 20 min
followed by cooling to room temperature). The sections were
blocked before the addition of primary antibodies and washed
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prior to the addition of secondary antibodies and DAPI
nuclear stain (1:500; Thermo Scientific). Slides were mounted
in Hardset Vectashield Mounting medium (Vector Laborato-
ries, Peterborough, UK) and analysed on a Nikon Eclipse 90i
Fluorescent Microscope.
Islet isolation Mice were terminally anaesthetised with CO2
then killed by cervical dislocation. Islets were isolated from
WT or Gpr120-knockout mice by liberase digestion
(1.4 mg/ml; Roche Applied Science, Indianapolis, IN, USA)
and separated by centrifugation. The islets were cultured
overnight in RPMI-1640 (10% FCS, 2 mmol/l L-glutamine,
100 U ml−1 penicillin, 100 mg ml−1 streptomycin, 11 mmol/l
glucose) at 37°C, 5% CO2.
Islet hormone secretion Four individual islets were dispensed
randomly into each well of a 24 well plate by hand and
incubated in Krebs–Ringer–HEPES buffer containing
0.5 mmol/l 3-isobutyl-1-methylxanthine (IBMX) at 37°C,
5% CO2 for 30 min before addition of the appropriate test
reagents or vehicle (DMSO, final concentration 0.3%) for a
further 2 h at 37°C, 5%CO2. Plates were centrifuged at 1,000g
for 1 min before the supernatant fraction was collected and
frozen in readiness for hormone assay. DHA sodium salt
(Sigma-Aldrich) was dissolved inwater at 37°C then complexed
to fatty acid free albumin (Sigma-Aldrich, 10% [wt/vol.]). The
final concentration of the DHA stock was 2 mmol/l and the pH
was adjusted to 7.4 before the solution was sterile filtered,
aliquoted and stored at −20°C. Hormone secretion was
measured after incubation of islets with 50 or 100 μmol/l
DHA in 1% BSA. Control islets were incubated with 1%
BSA.
Insulin and somatostatin secretion assays The insulin content
of the incubation medium was analysed using the high-range
HTRF insulin kit (62INSPEC, Cisbio Bioassays, Codolet,
France) and fluorescence resonance energy transfer was mea-
sured on an Envision plate reader (PerkinElmer, Cambridge,
UK). The somatostatin content of the islet incubation medium
was measured using a somatostatin ELISA kit (Peninsula
Laboratories, Bachem Group, Bubendorf, Switzerland) and
absorbance was read at 450 nm with an Ultra Evolution
XFluor4 plate reader. All standard curves were plotted using
Origin 7.5 software (www.originlab.com).
Islet gene expression analysis CEL files from the GSE38642
series were downloaded from the NCBI Gene Expression
Omnibus (GEO) data repository (www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE38642; last accessed 1
December, 2013). This dataset contains gene expression data
of human pancreatic islets from 63 donors generated on
Affymetrix GeneChip Human Gene 1.0 ST arrays
(Affymetrix, High Wycombe, UK). Background adjustment
and quantile normalisation and summarisation were computed
in the Array Studio software (Omicsoft Corporation; www.
omicsoft.com) to generate Robust Multichip Average
expression values. Correlations of gene expression were
calculated based on log2 expression values using the Pearson
correlation.
Statistical analysis Data are expressed as the mean values ±
SEM and statistical analysis was carried out using Student’s
t test and a one- or two-way ANOVAwith post hoc analysis,
as appropriate. Each experiment was performed on a mini-
mum of three separate occasions with five or more replicates
in any given experiment. Differences were considered signif-
icant when p<0.05.
Results
GPR120 is expressed in a subset of endocrine cells located
peripherally in mouse islets GPR120 is reportedly expressed
in the gastrointestinal tract of mice [6, 23–25] and, in confir-
mation of this, sections of colon from KO/KI animals treated
to reveal β-galactosidase activity, and by inference GPR120,
demonstrated a distinct staining pattern within specific lumi-
nal epithelial cells (Fig. 1c). This pattern was absent from the
WT animals (Fig. 1a). Importantly, similarly stained
cells were also observed in the islets of Langerhans of
KO/KI mice upon exposure to the substrate (Fig. 1d), but
were absent in WT animals (Fig. 1b). These cells comprised
only a small subpopulation of the total endocrine cell
Fig. 1 β-galactosidase (as a surrogate for GPR120) is expressed in
mouse colon and peripheral cells in the islets of Langerhans. WT (a)
colon and (b) pancreas, and KO/KI (c) colon and (d) pancreas cryosec-
tions were recovered and stained using an X-gal reporter kit. Images were
captured under brightfield illumination and β-galactosidase positive cells
are shown in blue
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complement of each islet and were arranged peripherally
within the islet mantle.
GPR120 co-localises mainly with somatostatin in murine
islets To establish the islet cell type in which β-gal (as a
surrogate for GPR120) is expressed in murine islets of
Langerhans, dual-immunofluorescence staining was per-
formed in paraffin-embedded pancreas sections recovered
from WT and KO/KI animals. In accord with data obtained
from the enzymat ic s ta in , immunoreac t iv i ty to
β-galactosidase was detected in a subset of endocrine cells
at the islet periphery in the KO/KI pancreas (Fig. 2). This was
restricted to the cell nuclei, as expected, since the β-gal
construct contained a nuclear localisation signal. Immunore-
activity to β-gal was not seen in the nuclei of insulin positive
cells but rather appeared to co-localise predominantly with
cells expressing somatostatin (Fig. 2). In addition, a minority
of glucagon positive cells had β-gal positive nuclei (Fig. 2,
white arrow). Among 197 alpha cells examined, 29 were
positive for β-gal (14.7%). By contrast, examination of
>150 somatostatin positive cells in multiple islets revealed
that all were also positive for β-gal.
Effects of GPR120 ligands on somatostatin secretion Since
GPR120 appears to be expressed predominantly in delta cells,
the effects of selective ligands on somatostatin secretion were
investigated. Initially, the responses of isolatedmurine islets to
known stimuli were studied as a means to validate the hor-
mone assay system. Accordingly, it was found that a rise in the
glucose concentration from 3 to 16.6 mmol/l enhanced so-
matostatin secretion from isolated islets (Fig. 3). Similarly,
incubation with 100 nmol/l glipizide (Glip) also augmented
somatostatin secretion from islets incubated with 3 mmol/l
glucose and the levels achieved were similar to those found
upon exposure to 16.6 mmol/l glucose. By contrast, the mus-
carinic cholinergic agonist carbachol (CCh) failed to alter the
rate of somatostatin secretion from islets incubated with
3 mmol/l glucose but significantly attenuated somatostatin
secretion from islets incubated with 16.6 mmol/l glucose
(Fig. 3).
In order to investigate whether or not the activation of
GPR120 exerts an influence on somatostatin secretion, three
structurally distinct GPR120 agonists were employed. Two of
these compounds (AZ-423 and AZ-670) are proprietary to
AstraZeneca while the third (Metabolex 36; CymaBay Ther-
apeutics (formerly Metabolex), San Francisco, CA, USA) has
been developed independently as a selective agonist of
GPR120 [12]. All three agonists have >100-fold selectivity
for GPR120 vs murine GPR40 and their selectivity is
summarised in ESM Table 1. In multiple experiments, all
three of the agonists tended to lower the basal rate of somato-
statin secretion achieved when islets were incubated with
3 mmol/l glucose. Moreover, under stimulating conditions
(i.e. in the presence of 16.6 mmol/l glucose) each consistently
caused a significant reduction in hormone release (Fig. 4).
In view of these results, the effects of Metabolex 36 were
studied in more detail (Fig. 5). This reagent inhibited glucose-
induced somatostatin secretion in a dose-dependent manner
when islets were incubated under either maximal stimulating
conditions (16.6 mmol/l) or with an intermediate glucose
concentration (8 mmol/l). Maximal inhibition was achieved
with 30 μmol/l of the ligand. By contrast, Metabolex 36 had
no effect on insulin secretion under either basal or glucose
stimulating conditions.
Effect of a GPR120 agonist on glucose-induced somatostatin
secretion from the islets of Gpr120-knockout mice To confirm
that the actions of Metabolex 36 reflect its ability to activate
GPR120, the somatostatin secretion experiments were repeat-
ed in islets from KO/KI animals. Islets were isolated from 16
WT and 16 Gpr120-knockout mice on four separate occa-
sions, and somatostatin secretion was monitored (Fig. 6). As
seen previously, Metabolex 36 attenuated glucose-induced
somatostatin secretion from the islets of WT animals. KO/KI
animals responded normally to glucose, with a two- to three-
fold increase in somatostatin secretion when the glucose
Insulin Glucagon Somatostatin
Fig. 2 β-galactosidase (as a surrogate for GPR120) is localised mainly
within the delta cells of mouse islets of Langerhans. Formalin-fixed,
paraffin-embedded pancreas sections from KO/KI mice were stained by
immunofluorescence for the presence of β-galactosidase (red), and each
of the three islet hormones insulin, glucagon and somatostatin (green) as
shown. Nuclei were stained with DAPI (blue). Images were captured on a
fluorescent microscope. The white arrow indicates a cell stained positive-
ly for both β-galactosidase and glucagon
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concentration was raised from 3 to 16.6 mmol/l, but in islets
from these mice Metabolex 36 failed to significantly reduce
glucose-induced somatostatin secretion (Fig. 6).
Effects of pertussis toxin on the actions of Metabolex 36 in
mouse islets In order to probe the signal transduction mecha-
nism by which GPR120 exerts its effects in murine islets,
pertussis toxin (Ptx) was employed. This agent ADP-
ribosylates the alpha subunits of G-proteins belonging to the
Gi/Go family, thereby inhibiting their signalling functions. As
a positive control for the actions of Ptx, both insulin and
somatostatin secretion were measured in parallel and various
agents were employed that are known to influence hormone
secretion in a Ptx-sensitive manner. Incubation of murine
islets with 16.6 mmol/l glucose resulted in a 9–10-fold






























3 mmol/l glucose 16.6 mmol/l glucose
Fig. 3 Effects of glucose, Glip and CCh on somatostatin secretion from
murine islets of Langerhans. Mouse islets were isolated, cultured over-
night and incubated for 2 h with 3 mmol/l or 16.6 mmol/l glucose in the
presence or absence of 100 nmol/l Glip or 500 μmol/l CCh as shown. The
medium was supplemented with 500 μmol/l IBMX. The supernatant
fraction was sampled and somatostatin secretion was measured by
ELISA. Data are presented as mean values ± SEM and the experiment
was repeated on a minimum of three separate occasions. **p<0.01 vs































































3 mmol/l glucose 16.6 mmol/l glucose
Fig. 4 Effects of selective GPR120 agonists on somatostatin secretion
from isolated mouse islets of Langerhans. Mouse islets were isolated,
cultured overnight and incubated for 2 h with 3 mmol/l or 16.6 mmol/l
glucose in the absence or presence of 100 nmol/l Glip, 500 μmol/l CCh or
30 μmol/l of each of three GPR120 agonists (Metabolex 36 [Metab 36],
AZ-423 and AZ-670). The incubation medium was supplemented with
500 μmol/l IBMX. Following incubation, the supernatant fraction was
collected and analysed for somatostatin secretion by ELISA. Data are
presented as mean values ± SEM and the experiment was repeated on a
minimum of three separate occasions. **p<0.01 vs 3 mmol/l glucose















































































Fig. 5 Effects of the GPR120 agonist Metabolex 36 on glucose-induced
somatostatin secretion from isolated mouse islets of Langerhans. Mouse
islets were isolated, cultured overnight and incubated for 2 h in the
presence of 8 mmol/l or 16.6 mmol/l glucose in the absence or presence
of 500 μmol/l CCh or increasing concentrations of Metabolex 36 (Metab
36) (3, 10 and 30 μmol/l). The incubation medium was supplemented
with 500 μmol/l IBMX. The supernatant fraction was sampled and
somatostatin secretion was measured by ELISA. Data are presented as
mean values ± SEM and the experiment was repeated on a minimum of
five separate occasions. **p<0.01 vs 8 mmol/l glucose alone; ††p<0.01







































































16.6 mmol/l glucose 16.6 mmol/l glucose
WT Gpr120-knockout
Fig. 6 The inhibitory effects of Metabolex 36 on somatostatin secretion
are lost in Gpr120-knockout animals. Islets were isolated from 16 WT
and 16 Gpr120-knockout animals, cultured overnight and treated with 3
or 16.6 mmol/l glucose in the absence or presence of 500 μmol/l CCh or
Metabolex 36 (Metab 36) (10 or 30 μmol/l) for 2 h. The incubation
medium was supplemented with 500 μmol/l IBMX. After this time, the
supernatant fraction was sampled and somatostatin secretion was
analysed by ELISA. Data from individual animals were recorded sepa-
rately and are presented from a representative experiment (n=5 for each
data point). **p<0.01 vs 16.6mmol/l glucose alone; NS, not significantly
different from 16.6 mmol/l glucose alone
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increase in insulin secretion and the magnitude of this re-
sponse was not influenced by prior incubation with
100 ng/ml Ptx (Fig. 7a). Addition of the alpha2-
adrenoceptor agonist, noradrenaline (norepinephrine;
1 μmol/l) significantly attenuated glucose-induced insulin
secretion and, as expected from previous work [26], this
response was abrogated upon preincubation with Ptx.
Similarly, although Ptx had no significant effect on rates
of somatostatin secretion from islets incubated with
either 3 mmol/l glucose or 16.6 mmol/l glucose alone;
it reduced the inhibitory actions of CCh on somatostatin
secretion seen when islets were treated with 16.6 mmol/l
glucose (Fig. 7b). Importantly, Ptx also attenuated the inhib-
itory effect of Metabolex 36 on glucose-induced somatostatin
secretion.
Effects of DHA on insulin and somatostatin secretion from
mouse islets In view of the finding that selective, synthetic
GPR120 agonists cause inhibition of somatostatin secretion it
was of interest to also test the effects of a putative physiolog-
ical ligand. Accordingly, the response to the n-3 fatty acid
DHAwas studied (Fig. 8). In contrast to Metabolex 36, DHA
failed to attenuate glucose-induced somatostatin secretion
from islets isolated from either WTorGpr120-knockout mice
(Fig. 8a). Importantly, despite the lack of response to DHA,
the inhibition mediated by Metabolex 36 was retained in WT
islets in these experiments and was lost after knockout of
GPR120. To verify that DHA was active in the islets under
16.6 mmol/l glucose























































Fig. 7 Effects of Ptx on agonist-regulated insulin or somatostatin secre-
tion from mouse islets of Langerhans. Mouse islets were isolated and
cultured overnight in the presence (light grey bars) or absence (black bars)
of 100 ng/ml Ptx. They were then exposed for 2 h to media containing
3mmol/l or 16.6 mmol/l glucose in the absence or presence of 500 μmol/l
CCh, 30 μmol/l Metabolex 36 or 1 μmol/l noradrenaline (norepineph-
rine). The incubation mediumwas supplemented with 500 μmol/l IBMX.
Following incubation, the supernatant fraction was sampled and assayed
for either (a) insulin or (b) somatostatin secretion. Data are presented as
mean values ± SEM and the experiment was repeated on a minimum of
three separate occasions. *p<0.05 compared with the relevant control in



















































16.6 mmol/l glucose 16.6 mmol/l glucose
WT GPR120 knockout






















































Fig. 8 Effects of DHA on somatostatin or insulin secretion from islets of
WTorGpr120-knockout animals. Islets were isolated from threeWTand
three Gpr120-knockout animals, cultured overnight and treated with 3 or
16.6 mmol/l glucose (glc) in the absence or presence of DHA (50 or
100 μmol/l) or Metabolex 36 (Metab 36) (30 μmol/l) for 2 h. The
incubation mediumwas supplemented with 500 μmol/l IBMX. After this
time, the supernatant fraction was sampled and assayed for either (a)
somatostatin or (b) insulin secretion. Data from each animal were record-
ed separately and are presented from a representative experiment (n=5 for
each data point). **p<0.01 vs somatostatin secretion in the presence of
16.6 mmol/l glucose alone; †p<0.05 vs insulin secretion in the presence
of 16.6 mmol/l glucose alone; ††p<0.01 vs insulin secretion in the
presence of 16.6 mmol/l glucose alone
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the conditions employed, insulin secretion was also measured
in the same samples. DHA dose-dependently potentiated in-
sulin secretion from WT islets but it was ineffective in islets
lacking GPR120 (Fig. 8b).
Expression patterns of GPR120 in human islets Having
established that, in murine islets, GPR120 is primarily
expressed in delta cells and that it may regulate somatostatin
secretion, it was considered important to extend this analysis
to determine the expression patterns of GPR120 in human
islet cells. In practice, this proved problematic because, al-
though a variety of antisera that are thought to be reactive
against GPR120 are available commercially, in our study the
specificity of these reagents could not be verified. Thus, we
adopted a different approach by analysing the correlation
between GPR120 expression at the mRNA level with other
genes that are expressed differentially in the various endocrine
cell types present within islets.
The GSE38642 dataset contains expression levels of
28,869 transcripts in islets from each of 63 donors (54 nondi-
abetic and nine type 2 diabetic subjects [22]). Correlations
were made between the expression of various genes present in
individual endocrine cell types with that of GPR120 (Probeset
7929344) to establish which cell type is most strongly corre-
lated with expression of GPR120 (Table 1). The most robust
correlation (r=0.66, p=5.2×10−9) was between GPR120 and
somatostatin (Probeset 8092682). Correlations with other endo-
crine cell markers were weaker: insulin r=0.60, p=2.3×10 −7;
glucagon r=0.41, p=0.0009; ghrelin r=0.40, p=0.0011; pan-
creatic polypeptide r=0.16, p=0.21 (Table 1). Similarly, marker
genes for duct, acinar, endothelial, pancreatic stellate and mye-
loid cells were detectable but had correlation coefficients with
GPR120 <−0.089 (Table 1).
Discussion
The expression pattern of GPR120 within the endocrine pan-
creas remains controversial with initial reports suggesting its
absence from human islets of Langerhans as well as from
clonal mouse pancreatic beta cells [6, 19]. By contrast, we
[21] as well as Gotoh et al [15] and Kebede et al [20] have
reported that GPR120 is present at the mRNA level in rodent
pancreas beta cell lines and in rat or mouse islets. In addition,
Taneera et al [22] have reported GPR120 expression in human
islets. In the present work, we confirm the outcomes of these
latter studies by demonstrating the expression of GPR120
mRNA in mouse and human islets. However, we also show
that the receptor is not present in the majority of islet endo-
crine cells and, consistent with the initial reports of Hirasawa
et al [6] we find no evidence that it is present in mouse beta
cells (although, as noted above, in earlier work we detected
GPR120 in various clonal rat beta cells, suggesting either that
species differences exist or that clonal rat beta cells are unrep-
resentative of primary cells with respect to GPR120
expression).
Despite our failure to detect GPR120 in mouse beta cells,
the use of a KO/KI approach revealed that the GPR120
promoter is functionally active within a subset of endocrine
cells located peripherally within the mantle of mouse islets.
This was confirmed both by a colourimetric assay, in which
the activity of the enzyme was detected directly in unfixed
cryosections, and by immunofluorescence analysis using an
antiserum directed against β-gal . Moreover, the
immunopositive cells were co-stained by an antiserum direct-
ed against somatostatin suggesting that they were delta cells.
Taken together, these data imply that GPR120 is preferentially
localised within the delta cells of mouse islets but that it is
absent from beta cells. A small proportion of glucagon posi-
tive islet cells (∼15%) also expressed β-gal, which is consis-
tent with a recent report that the clonal alpha cell line, alpha-
TC1, may express GPR120 [27].
In order to verify the situation in human islets, we corre-
lated the abundance of GPR120 mRNA with other known
endocrine cell markers. This revealed that expression of
GPR120 was more strongly correlated with somatostatin than
with either insulin or glucagon in human islets. Hence, al-
though we cannot conclude that human alpha and beta cells
are devoid of GPR120, these results imply that the receptor is
enriched in the delta cell population in human islets, consistent
with our findings in mice.
Having established that GPR120 is expressed predomi-
nantly in the somatostatin positive delta cells of murine islets
of Langerhans, further studies were initiated to examine the
functional role of GPR120 in these cells. The delta cells
typically comprise 5–10% of the endocrine population of
mouse islets and they synthesise and secrete somatostatin-
14, an isoform that accounts for approximately 5% of
Table 1 GPR120 expression correlates most highly with the expression
of somatostatin in the human pancreas







Pancreatic polypeptide PP 0.16
Ghrelin Epsilon 0.40
Elastin Acinar −0.44
Keratin 7 Ductal −0.42




Gene expression analysis was used to correlate the expression of GPR120
with other markers of pancreatic endocrine and exocrine cells in samples
from each of 63 individual pancreas donors within the GEO dataset
GSE38642. The strongest correlation was with somatostatin
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circulating somatostatin [28, 29]. Accordingly, we employed
an assay system to monitor somatostatin-14 secretion from
mouse islets and examined the effects of various stimuli,
including three selective GPR120 agonists. The results re-
vealed that a rise in glucose concentration from 3 to
16.6 mmol/l was associated with a two- to threefold increase
in somatostatin secretion and that the sulfonylurea Glip also
promoted somatostatin secretion. These data are consistent
with a substantial body of earlier work [29–39]. In addition,
we observed that the muscarinic cholinergic agonist CCh
inhibited glucose-induced somatostatin secretion, in accord
with Hauge-Evans et al [33, 34]. Importantly, it should be
noted that muscarinic cholinergic receptor isoforms are
expressed differentially in beta and delta cells and, as a con-
sequence, their responses to parasympathetic stimulation are
different. Beta cells express the M3 isoform (whose agonists
stimulate insulin secretion), whereas the M2 and M4 isoforms
are involved in the parasympathetic inhibition of somatostatin
secretion from delta cells [33]. In our studies, each of the three
GPR120 agonists tested caused a marked inhibition of
glucose-induced somatostatin secretion. This implies that
GPR120 may be coupled to a signalling pathway that medi-
ates inhibition of somatostatin secretion from delta cells. The
GPR120 agonists did not alter the rate of insulin secretion
from mouse islets under any condition studied. This is con-
sistent with the observation that GPR120 is not expressed in
beta cells, but it also implies that the paracrine effects of
somatostatin on the beta cells (which might be expected to
have been relieved during incubation with GPR120 agonists,
thereby leading to enhanced insulin secretion) were only
minimally effective under the conditions of static incubation
used in the present experiments.
To verify that the effects observed were due to agonism at
GPR120, islets from Gpr120-knockout animals were utilised
and the responses to the GPR120 agonist Metabolex 36 were
compared with those in WT mice. The results revealed that
although the GPR120 agonist consistently inhibited glucose-
induced somatostatin secretion fromWT islets, it was ineffec-
tive in islets from Gpr120-knockout mice.
Previous studies have suggested that the C16 saturated
fatty acid palmitate inhibits somatostatin secretion [40] but it
is not known whether or not this reflects agonism at GPR120
since palmitate exerts pleiotropic effects in islet cells. Thus,
we tested the effects of DHA, an n-3 fatty acid, which has
been proposed as a physiological GPR120 agonist [2, 10, 11].
However, unlike Metabolex 36, DHA (up to 100 μmol/l)
failed to attenuate glucose-induced somatostatin secretion.
This may be because DHA exerts multiple effects on islet
cells (including both metabolic and receptor-mediated re-
sponses) but, whatever the reason, these results emphasise
the value of selective, synthetic agonists for delineating the
role of GPR120 in islets. As confirmation that DHA was
active under the conditions employed, insulin secretion was
also studied and it was shown that the fatty acid dose-
dependently potentiated insulin secretion from WT murine
islets (Fig. 8b). However, it is interesting to note that DHA
failed to increase insulin secretion from the Gpr120-knockout
islets. The reasons for this are unclear but the results could be
taken to imply that activation of GPR120 plays a facilitatory
role in mediating the enhanced insulin secretion. However,
this conclusion is not supported by data obtained with the
more selective GPR120 agonist Metabolex 36, which
failed to promote insulin secretion under any condition studied
(Figs 7a and 8b).
Using transfection models a number of different coupling
mechanisms have been proposed for GPR120. Initially, it was
suggested that GPR120 couples to the Gαq G-protein as
HEK293 cells stably expressing the receptor responded to
the GPR120 agonist linolenic acid, with an increase in intra-
cellular Ca2+ and induction of downstream signalling mole-
cules of the extracellular signal-regulated kinase/
phosphatidylinositol 3-kinase signalling pathway [6]. Similar
effects were also seen in the human intestinal cell line STC-1,
where agonism at GPR120 was protective against serum
withdrawal, and these protective effects were lost in the pres-
ence of a phospholipase C inhibitor U73122 [41]. In our
studies, the involvement of Gq has not been tested directly
but we consider it unlikely that this mechanism operates in
mouse delta cells since this would result in enhanced hormone
secretion by virtue of the increased cytosolic Ca2+ levels.
Rather, we noted a decline in somatostatin secretion. Impor-
tantly, it should be noted that the calculated potency of each of
the various GPR120 agonists has been derived mainly from
analyses in which the activation of Gq was the functional
readout. Since we now show that, in islets, the responses are
unlikely to be mediated via Gq it is possible that their poten-
cies may be altered in the islet system. This might, therefore,
account for the finding that 3 μmol/l Metabolex-36 was inef-
fective as an inhibitor of somatostatin secretion (Fig. 4),
whereas this concentration is some threefold greater than its
calculated half maximal effective concentration (EC50) (ESM
Table 1).
From our studies it appears that GPR120 may couple, at
least in part, to the Ptx-sensitive Gαi in murine islets. Thus, we
observed that preincubation of islets with Ptx significantly
attenuated the inhibitory effects of Metabolex-36 on
glucose-induced somatostatin secretion in a similar manner
to that seen previously with CCh [33]. Since Gi is typically
coupled to adenylate cyclase these results imply that GPR120
is likely to reduce cAMP levels in murine islets, although it
should be noted that the inhibition of hormone secretion via Gi
may also involve a range of other mechanisms [42]. An
additional consideration is that in order to facilitate the mea-
surement of somatostatin secretion the incubation medium
was supplemented with IBMX, which would be expected to
mediate a rise in intracellular cAMP. Hence, any attenuation of
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cAMP synthesis would be manifest as a reduction in stimulated
somatostatin secretion, and we deduce that this is the mechanism
by which GPR120 agonists exert their effects. Overall, therefore,
these data strongly suggest that GPR120 is coupled to Gi in
mouse delta cells and that this leads to reduced rates of somato-
statin secretion under conditions of glucose stimulation.
Funding We are grateful for financial support in the form of a BBSRC-
CASE studentship to VMS (grant ref: GD102003-102). We also thank
Diabetes UK for grant support (ref: 12/0004505).
Duality of interest statement KJB, CL, MSW, MH, XX and DMS are
shareholders in AstraZeneca. The remaining authors declare that they
have no duality of interest in connection with this manuscript.
Contribution statement VMS designed the study, performed experi-
ments, analysed data and wrote the manuscript. SD, KJB, MSW, CL and
XX performed experiments, analysed data, contributed to study design
and edited the manuscript. MH analysed data, performed bioinformatics
analysis and edited the manuscript. DMS contributed to the study design
and reviewed and edited the manuscript. NGMwas responsible for study
design, wrote the manuscript and is responsible for the integrity of the
study as a whole. All authors have approved the final version for
publication.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Fredriksson R, Hoglund PJ, Gloriam DEI, Lagerstrom MC,
Schioth HB (2003) Seven evolutionarily conserved human
rhodopsin G protein-coupled receptors lacking close relatives.
FEBS Lett 554:381–388
2. Burns RN, Moniri NH (2010) Agonism with the omega-3 fatty acids
[alpha]-linolenic acid and docosahexaenoic acid mediates phosphor-
ylation of both the short and long isoforms of the human GPR120
receptor. Biochem Biophys Res Commun 396:1030–1035
3. Watson SJ, Brown AJ, Holliday ND (2012) Differential signaling by
splice variants of the human free fatty acid receptor GPR120.
Mol Pharmacol 81:631–642
4. Cartoni C, Yasumatsu K, Ohkuri T et al (2010) Taste preference for
fatty acids is mediated by GPR40 and GPR120. J Neurosci 30:8376–
8382
5. Hara T, Hirasawa A, Ichimura A, Kimura I, Tsujimoto G (2011) Free
fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets
for metabolic disorders. J Pharm Sci 100:3594–3601
6. Hirasawa A, Keiko T, Awaji T et al (2005) Free fatty acids regulate
gut incretin glucagon-like peptide-1 secretion through GPR120.
Nat Med 11:90–94
7. Ichimura A, Hirasawa A, Hara T, Tsujimoto G (2009) Free fatty acid
receptors act as nutrient sensors to regulate energy homeostasis.
Prostaglandins Lipid Mediat 89:82–88
8. Ichimura A, Hirasawa A, Poulain-Godefroy O et al (2012)
Dysfunction of lipid sensor GPR120 leads to obesity in both mouse
and human. Nature 483:350–354
9. Miyauchi S, Hirasawa A, Iga T et al (2009) Distribution and regula-
tion of protein expression of the free fatty acid receptor GPR120.
Naunyn Schmiedeberg’s Arch Pharmacol 379:427–434
10. Oh DY, Talukdar S, Bae EJ et al (2010) GPR120 is an omega-3 fatty
acid receptor mediating potent anti-inflammatory and insulin-
sensitizing effects. Cell 142:687–698
11. Talukdar S, Olefsky JM, Osborn O (2011) Targeting GPR120 and
other fatty acid-sensing GPCRs ameliorates insulin resistance and
inflammatory diseases. Trends Pharmacol Sci 32:543–550
12. Holliday ND, Watson S-J, Brown AJH (2012) Drug discovery op-
portunities and challenges at G protein coupled receptors for long
chain free fatty acids. Front Endocrinol 2:1–12
13. TanakaT,KatsumaS,Adachi T, KoshimizuT,HirasawaA, TsujimotoG
(2007) Free fatty acids induce cholecystokinin secretion through
GPR120. Naunyn Schmiedeberg’s Arch Pharmacol 377:523–527
14. Tanaka T, Yano T, Adachi T, Koshimizu TA, Hirasawa A,
Tsujimoto G (2008) Cloning and characterization of the rat
free fatty acid receptor GPR120: in vivo effect of the natural
ligand on GLP-1 secretion and proliferation of pancreatic beta cells.
Naunyn Schmiedeberg’s Arch Pharmacol 377:515–522
15. Gotoh C, HongYH, Iga Tet al (2007) The regulation of adipogenesis
through GPR120. Biochem Biophys Res Commun 354:591–597
16. Matsumura S, Eguchi A, Mizushige T et al (2009) Colocalization of
GPR120 with phospholipase-Cbeta2 and alpha-gustducin in the taste
bud cells in mice. Neurosci Lett 450:186–190
17. Matsumura S, Mizushige T, Yoneda Tet al (2007) GPR expression in
the rat taste bud relating to fatty acid sensing. Biomed Res 28:49–55
18. Cintra DE, Ropelle ER, Moraes JC et al (2012) Unsaturated fatty
acids revert diet-induced hypothalamic inflammation in obesity.
PLoS ONE 7:e30571
19. Costanzi S, Neumannm S, Gershengorn MC (2008) Seven
transmembrane-spanning receptors for free fatty acids as therapeutic
targets for diabetes mellitus: pharmacological, phylogenetic and drug
discovery aspects. J Biol Chem 238:16269–16273
20. KebedeMA, Alquier T, LatourMG, Poitout V (2009) Lipid receptors
and islet function: therapeutic implications? Diabetes Obes Metab
11(Suppl 4):10–20
21. Morgan NG, Dhayal S (2009) G-protein coupled receptors
mediating long chain fatty acid signalling in the pancreatic
beta-cell. Biochem Pharmacol 78:1419–1427
22. Taneera J, Lang S, Sharma A et al (2012) A systems genetics
approach identifies genes and pathways for type 2 diabetes in human
islets. Cell Metab 16:122–134
23. FredborgM, Theil PK, Jensen BB, Purup S (2012) G protein-coupled
receptor120 (GPR120) transcription in intestinal epithelial cells is
significantly affected by bacteria belonging to the Bacteroides,
Proteobacteria, and Firmicutes phyla. J Anim Sci 90(Suppl 4):10–12
24. Hara T, Hirasawa A, Sun Q et al (2009) Novel selective
ligands for free fatty acid receptors GPR120 and GPR40.
Naunyn Schmiedeberg’s Arch Pharmacol 380:247–255
25. Li Y, Kokrashvili Z, Mosinger B, Margolskee RF (2013)
Gustducin couples fatty acid receptors to GLP-1 release in colon.
Am J Physiol Endocrinol Metab 304:E651–E660
26. Morgan NG, Montague W (1985) Studies on the mechanism of
inhibition of glucose-stimulated insulin secretion by noradrenaline
in rat islets of Langerhans. Biochem J 226:571–576
27. Whalley NM, Pritchard LE, Smith DM, White A (2011) Processing
of proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine
mechanism enabling GLP-1 to act on beta-cells? J Endocrinol 211:
99–106
28. Muroyama A, Uehara S, Yatsushiro S et al (2004) A novel variant of
ionotropic glutamate receptor regulates somatostatin secretion from
delta-cells of islets of Langerhans. Diabetes 53:1743–1753
29. Strowski MZ, Blake AD (2008) Function and expression of somato-
statin receptors of the endocrine pancreas. Mol Cell Endocrinol 286:
169–179
1190 Diabetologia (2014) 57:1182–1191
30. Braun M, Ramracheya R, Amisten S et al (2009) Somatostatin
release, electrical activity, membrane currents and exocytosis in
human pancreatic delta cells. Diabetologia 52:1566–1578
31. de Heer J, Rasmussen C, Coy DH, Holst JJ (2008) Glucagon-like
peptide-1, but not glucose-dependent insulinotropic peptide,
inhibits glucagon secretion via somatostatin (receptor sub-
type 2) in the perfused rat pancreas. Diabetologia 51:2263–
2270
32. Egido EM, Silvestre RA, Hernandez R, Marco J (2004) Exendin-4
dose-dependently stimulates somatostatin and insulin secretion in
perfused rat pancreas. Horm Metab Res 36:595–600
33. Hauge-Evans AC, Anderson RL, Persaud SJ, Jones PM
(2012) Delta cell secretory responses to insulin secretagogues
are not mediated indirectly by insulin. Diabetologia 55:1995–
2004
34. Hauge-Evans AC, King AJ, Carmignac D et al (2009) Somatostatin
secreted by islet delta-cells fulfills multiple roles as a paracrine
regulator of islet function. Diabetes 58:403–411
35. Hellman B, Salehi A, Grapengiesser E, Gylfe E (2012) Isolated
mouse islets respond to glucose with an initial peak of glucagon
release followed by pulses of insulin and somatostatin in
antisynchrony with glucagon. Biochem Biophys Res Commun 417:
1219–1223
36. Julien S, Laine J, Morisset J (2004) The rat pancreatic islets: a reliable
tool to study islet responses to cholecystokinin receptor occupation.
Regul Pept 121:73–81
37. Kelly C, Flatt PR, McClenaghan NH (2010) Cell-to-cell communi-
cation and cellular environment alter the somatostatin status of delta
cells. Biochem Biophys Res Commun 399:162–166
38. Kelly C, Parke HG, McCluskey JT, Flatt PR, McClenaghan NH
(2010) The role of glucagon- and somatostatin-secreting cells in the
regulation of insulin release and beta-cell function in heterotypic
pseudoislets. Diabetes Metab Res Rev 26:525–533
39. Silvestre RA, Egido EM, Hernandez R, Marco J (2005) Tungstate
stimulates insulin release and inhibits somatostatin output in the
perfused rat pancreas. Eur J Pharmacol 519:127–134
40. Olofsson CS, Salehi A, Göpel SO, Holm C, Rorsman P (2004)
Palmitate stimulation of glucagon secretion in mouse pancreatic
alpha-cells results from activation of L-type calcium channels and
elevation of cytoplasmic calcium. Diabetes 53:2836–2843
41. Katsuma S, Hatae N, Yano T et al (2005) Free fatty acids inhibit
serum deprivation-induced apoptosis through GPR120 in a murine
enteroendocrine cell line STC-1. J Biol Chem 280:19507–19515
42. Straub SG, SharpGWG(2012) Evolving insights regardingmechanisms
for inhibition of insulin secretion by norepinephrine and heterotrimeric
G-proteins. Am J Physiol Cell Physiol 302:C1687–C1698
Diabetologia (2014) 57:1182–1191 1191
